Role of Microribonucleic acid in the Carcinogenesis of Non-Small-Cell Lung Cancer
- Authors: Gubenko M.S.1, Loginov V.I.1, Burdennyy A.M.1, Pronina I.V.1, Khokhlova S.V.2, Pertsov S.S.3
-
Affiliations:
- Institute of General Pathology and Pathophysiology
- National Medical Research Center of Obstetrics, Gynecology and Perinatology named after academician V. I. Kulakov
- P. K. Anokhin Research Institute of Normal Physiology
- Issue: Vol 30, No 1 (2022)
- Pages: 123-132
- Section: Reviews
- URL: https://journals.rcsi.science/pavlovj/article/view/71395
- DOI: https://doi.org/10.17816/PAVLOVJ71395
- ID: 71395
Cite item
Abstract
INTRODUCTION: Lung cancer is the most common malignant neoplasm. Despite advances in target therapy, immunotherapy, and chemotherapy, non-small cell lung cancer remains the major cause of cancer-related death worldwide. Tumor development is a complex process that depends on the influence of environmental factors and genetic predisposition. Although oncogenic factors have received much attention, the main mechanisms for oncogenesis are still poorly understood. Thus, studying the oncogenic mechanisms, including those with the involvement of microribonucleic acid (microRNA), is important for the diagnostics and treatment of malignant neoplasms. MicroRNA (miRNA) belong to the class of small non-coding ribonucleic acids that are involved in various cellular biological processes, including epithelial–mesenchymal transition, apoptosis, proliferation, invasion, and metastatic dissemination of cancer cells. Recent publications show that the course of the oncological disease can be predicted by evaluating the expressions of some miRNAs. Therefore, miRNAs serve as promising diagnostic and therapeutic targets in oncological diseases.
CONCLUSION: This review summarizes data on the role in carcinogenesis and prognostic significance of several miRNA (i.e., miRNA-128, -4500, -222, -224, -124, -125b, -127, -129-2, -137, and -375) in non-small cell lung cancer.
Full Text
##article.viewOnOriginalSite##About the authors
Marina S. Gubenko
Institute of General Pathology and Pathophysiology
Email: artz_marina@mail.ru
ORCID iD: 0000-0001-5439-9713
SPIN-code: 4992-7397
Russian Federation, Moscow
Vitaliy I. Loginov
Institute of General Pathology and Pathophysiology
Email: werwolf2000@mail.ru
ORCID iD: 0000-0003-2668-8096
SPIN-code: 6249-5883
Cand. Sci. (Biol.)
Russian Federation, MoscowAleksey M. Burdennyy
Institute of General Pathology and Pathophysiology
Email: koldun.pro@mail.ru
ORCID iD: 0000-0002-9398-8075
SPIN-code: 4429-4288
Cand. Sci. (Biol.)
Russian Federation, MoscowIrina V. Pronina
Institute of General Pathology and Pathophysiology
Email: p.lenyxa@yandex.ru
ORCID iD: 0000-0002-0423-7801
SPIN-code: 5706-2369
Cand. Sci. (Biol.)
Russian Federation, MoscowSvetlana V. Khokhlova
National Medical Research Center of Obstetrics, Gynecology and Perinatology named after academician V. I. Kulakov
Email: svkhokhlova@mail.ru
ORCID iD: 0000-0002-4121-7228
SPIN-code: 6009-4616
MD, Dr. Sci. (Med.), Professor
Russian Federation, MoscowSergey S. Pertsov
P. K. Anokhin Research Institute of Normal Physiology
Author for correspondence.
Email: s.pertsov@mail.ru
ORCID iD: 0000-0001-5530-4990
SPIN-code: 3876-0513
MD, Dr. Sci. (Med.), Professor
Russian Federation, MoscowReferences
- Yang H–W, Liu G–H, Liu Y–Q, et al. Over–expression of microRNA-940 promotes cell proliferation by targeting GSK3beta and sFRP1 in human pancreatic carcinoma. Biomedicine & Pharmacotherapy. 2016;83:593–601. doi: 10.1016/j.biopha.2016.06.057
- Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54. doi: 10.1016/0092-8674(93)90529-y
- Esteller M. Non-coding RNAs in human disease. Nature Reviews. Genetics. 2011;12(12):861–74. doi: 10.1038/nrg3074
- Jin M, Zhang T, Liu C, et al. miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor–initiating cells. Cancer Research. 2014;74(15):4183–95. doi: 10.1158/0008-5472.CAN-14-0404
- Chen Z, Lai T–C, Jan Y–H, et al. Hypoxia–responsive miRNAs target argonaute 1 to promote angiogenesis. The Journal of Clinical Investigation. 2013;123(3):1057–67. doi: 10.1172/JCI65344
- Ho JJD, Metcalf JL, Yan MS, et al. Functional importance of Dicer protein in the adaptive cellular response to hypoxia. The Journal of Biological Chemistry. 2012;287(34):29003–20. doi: 10.1074/jbc.m112.373365
- Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010;467(7311):86–90. doi: 10.1038/nature09284
- Liu H–T, Xing A–Y, Chen X, et al. MicroRNA-27b, microRNA-101 and microRNA-128 inhibit angiogenesis by down–regulating vascular endothelial growth factor C expression in gastric cancers. Oncotarget. 2015;6(35):37458–70. doi: 10.18632/oncotarget.6059
- Markou A, Liang Y, Lianidou E. Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer. Clinical Chemistry and Laboratory Medicine. 2011;49(10):1591–603. doi: 10.1515/CCLM.2011.661
- Zhang R, Liu C, Niu Y, et al. MicroRNA-128-3p regulates mitomycin C-induced DNA damage response in lung cancer cells through repressing SPTAN1. Oncotarget. 2016;8(35):58098–107. doi: 10.18632/oncotarget.12300
- Zeng XC, Li L, Wen H, et al. MicroRNA-128 inhibition attenuates myocardial ischemia/reperfusion injury–induced cardiomyocyte apoptosis by the targeted activation of peroxisome proliferator–activated receptor gamma. Molecular Medicine Reports. 2016;14(1):129–36. doi: 10.3892/mmr.2016.5208
- Liu X, Gao Y, Lu Y, et al. Upregulation of NEK2 is associated with drug resistance in ovarian cancer. Oncology Reports. 2014;31(2):745–54. doi: 10.3892/or.2013.2910
- Zhao D, Han W, Liu X, et al. MicroRNA–128 promotes apoptosis in lung cancer by directly targeting NIMA–related kinase 2. Thoracic Cancer. 2017;8(4):304–11. doi: 10.1111/1759-7714.12442
- Zhang L, Qian J, Qiang Y, et al. Down–regulation of miR-4500 promoted non-small cell lung cancer growth. Cellular Physiology and Biochemistry. 2014;34(4):1166–74. doi: 10.1159/000366329
- Li Z–Y, Zhang Z–Z, Bi H, et al. MicroRNA-4500 suppresses tumor progression in non-small cell lung cancer by regulating STAT3. Molecular Medicine Reports. 2019;20(6):4973–83. doi: 10.3892/mmr.2019.10737
- Wei F, Ma C, Zhou T, et al. Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p. Molecular Cancer. 2017;16(1):132. doi: 10.1186/s12943-017-0694-8
- Ulivi P, Petracci E, Marisi G, et al. Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer. Journal of Clinical Medicine. 2019;8(2):131. doi: 10.3390/jcm8020131
- Wang Y, Lee ATC, Ma JZI, et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. The Journal of Biological Chemistry. 2008;283(19):13205–15. doi: 10.1074/jbc.m707629200
- Wang Y, Ren J, Gao Y, et al. MicroRNA-224 targets SMAD family member 4 to promote cell proliferation and negatively influence patient survival. PLoS One. 2013;8(7):e68744. doi: 10.1371/journal.pone.0068744
- Huang L, Dai T, Lin X, et al. MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells. Biochemical and Biophysical Research Communications. 2012;425(2):127–33. doi: 10.1016/j.bbrc.2012.07.025
- Goto Y, Nishikawa R, Kojima S, et al. Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. FEBS Letters. 2014;588(10):1973–82. doi: 10.1016/j.febslet.2014.04.020
- Wang H, Zhu L–J, Yang Y–C, et al. MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G₁/S transition and apoptosis by targeting p21(WAF1/CIP1). British Journal of Cancer. 2014;111(2):339–54. doi: 10.1038/bjc.2014.157
- Zhu X, Kudo M, Huang X, et al. Frontiers of MicroRNA Signature in Non-small Cell Lung Cancer. Frontiers in Cell and Developmental Biology. 2021;9:643942. doi: 10.3389/fcell.2021.643942
- Li Z, Wang X, Li W, et al. miRNA-124 modulates lung carcinoma cell migration and invasion. Clinical Pharmacology and Therapeutics. 2016;54(8):603–12. doi: 10.5414/CP202551
- Yang Q, Wan L, Xiao C, et al. Inhibition of LHX2 by miR-124 suppresses cellular migration and invasion in non-small cell lung cancer. Oncology Letters. 2017;14(3):3429–36. doi: 10.3892/ol.2017.6607
- Liu Y–Y, Zhang L–Y, Du W–Z. Circular RNA circ-PVT1 contributes to paclitaxel resistance of gastric cancer cells through the regulation of ZEB1 expression by sponging miR-124-3p. Bioscience Reports. 2019;39(12):BSR20193045. doi: 10.1042/BSR20193045
- Hu D, Li M, Su J, et al. Dual-targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells. Genetic Testing and Molecular Biomarkers. 2019;23(3):156–65. doi: 10.1089/gtmb.2018.0259
- Yan G, Li Y, Zhan L, et al. Decreased miR-124-3p promoted breast cancer proliferation and metastasis by targeting MGAT5. American Journal of Cancer Research. 2019;9(3):585–96.
- Cai J, Huang J, Wang W, et al. miR-124-3p Regulates FGF2-EGFR Pathway to Overcome Pemetrexed Resistance in Lung Adenocarcinoma Cells by Targeting MGAT5. Cancer Management and Research. 2020;12:11597–609. doi: 10.2147/CMAR.S274192
- Zhao Y, Bhattacharjee S, Jones BM, et al. Regulation of neurotropic signaling by the inducible, NF-kB-sensitive miRNA-125b in Alzheimer's disease (AD) and in primary human neuronal-glial (HNG) cells. Molecular Neurobiology. 2014;50(1):97–106. doi: 10.1007/s12035-013-8595-3
- Shaham L, Binder V, Gefen N, et al. MiR-125 in normal and malignant hematopoiesis. Leukemia. 2012;26(9):2011–8. doi: 10.1038/leu.2012.90
- Wang Y, Zhao M, Liu J, et al. MiRNA-125b regulates apoptosis of human non-small cell lung cancer via the PI3K/Akt/GSK3β signaling pathway. Oncology Reports. 2017;38(3):1715–23. doi: 10.3892/or.2017.5808
- Chen J, Wang M, Guo M, et al. miR-127 regulates cell proliferation and senescence by targeting BCL6. PLoS One. 2013;8(11):e80266. doi: 10.1371/journal.pone.0080266
- Guo L–H, Li H, Wang F, et al. The tumor suppress or roles of miR-433 and miR-127 in gastric cancer. International Journal of Molecular Sciences. 2013;14(7):14171–84. doi: 10.3390/ijms140714171
- Shi L, Wang Y, Lu Z, et al. miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop. Oncogene. 2017;36(12):1631–43. doi: 10.1038/onc.2016.332
- Xiao Y, Li X, Wang H, et al. Epigenetic regulation of miR-129-2 and its effects on the proliferation and invasion in lung cancer cells. Journal of Cellular and Molecular Medicine. 2015;19(9): 2172–80. doi: 10.1111/jcmm.12597
- Theriault BL, Dimaras H, Gallie BL, et al. The genomic landscape of retinoblastoma: a review. Clinical & Experimental Ophthalmology. 2014; 42(1):33–52. doi: 10.1111/ceo.12132
- Bin C, Xiaofeng H, Wanzi X. The effect of microRNA-129 on the migration and invasion in NSCLC cells and its mechanism. Experimental Lung Research. 2018;44(6):280–7. doi: 10.1080/01902148.2018.1536174
- Zhu X, Li Y, Shen H, et al. miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6. FEBS Letters. 2013;587(1):73–81. doi: 10.1016/j.febslet.2012.11.004
- Bi Y, Han Y, Bi H, et al. miR-137 impairs the proliferative and migratory capacity of human non-small cell lung cancer cells by targeting paxillin. Human Cell. 2014;27(3):95–102. doi: 10.1007/s13577-013-0085-4
- Zhang B, Liu T, Wu T, et al. microRNA-137 functions as a tumor suppressor in human non-small cell lung cancer by targeting SLC22A18. International Journal of Biological Macromolecules. 2015;74:111–8. doi: 10.1016/j.ijbiomac.2014.12.002
- Noguera–Uclés JF, Boyero L, Salinas A, et al. The Roles of Imprinted SLC22A18 and SLC22A18AS Gene Overexpression Caused by Promoter CpG Island Hypomethylation as Diagnostic and Prognostic Biomarkers for Non-Small Cell Lung Cancer Patients. Cancers (Basel). 2020;12(8):2075. doi: 10.3390/cancers12082075
- Shen H, Wang L, Ge X, et al. MicroRNA-137 inhibits tumor growth and sensitizes chemosensitivity to paclitaxel and cisplatin in lung cancer. Oncotarget. 2016;7(15):20728–42. doi: 10.18632/oncotarget.8011
- Wilting SM, Verlaat W, Jaspers A, et al. Methylation–mediated transcriptional repression of microRNAs during cervical carcinogenesis. Epigenetics. 2013;8(2):220–8. doi: 10.4161/epi.23605
- Yu L, Todd NW, Xing L, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. International Journal of Cancer. 2010;127(12):2870–8. doi: 10.1002/ijc.25289
- Li Y, Jiang Q, Xia N, et al. Decreased Expression of MicroRNA-375 in Nonsmall Cell Lung Cancer and its Clinical Significance. The Journal of International Medical Research. 2012;40(5):1662–9. doi: 10.1177/030006051204000505
- Cheng L, Zhan B, Luo P, et al. miRNA-375 regulates the cell survival and apoptosis of human non-small cell carcinoma by targeting HER2. Molecular Medicine Reports. 2017;15(3):1387–92. doi: 10.3892/mmr.2017.6112